eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
eXoZymes Inc. Announces Closing of $6 Million Public Offering
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today
eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff
eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST
CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference
CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference
CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference
Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees
eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today
eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST
eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity
eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months
eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health